The Relative Strength (RS) Rating for Illumina moved into a higher percentile Tuesday, as it got a lift from 67 to 78.
IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 in the early stages of their moves. See if Illumina can continue to show renewed price strength and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Illumina is trying to complete a consolidation with a 156.66 buy point. See if the stock can clear the breakout price in heavy trade.
Top and bottom line growth moved higher last quarter. Earnings were up 245%, compared to 13% in the prior report. Revenue increased from -5% to -3%. Look for the next report on or around Feb. 6.
The company holds the No. 5 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte is the top-ranked stock within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
